Kyle Hurth

Kyle Hurth

Auto-generated profile, based on publicly available information

Kyle Hurth

Department of Pathology, Keck School of Medicine, University of Southern California, Los Angeles, California

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2002 in Molecular Endocrinology
Verified
Journal Article
Closed access
ATAnobel Tamrazi
Anobel Tamrazi
KCKathryn E. Carlson
Kathryn E. Carlson
JDJonathan R. Daniels
Jonathan R. Daniels
KHKyle M. Hurth
Kyle M. Hurth
JKJohn A Katzenellenbogen
John A Katzenellenbogen
Nuclear receptors form strong dimers that are essential for their function as transcription factors, and it is thought that ligand binding can affect dimer stability. In this report, we describe convenient fluorescence resonance energy transfer (FRET)-based methods for measuring the thermodynamic and kinetic stability of dimers of the estrogen receptor-alpha ligand-binding domain (ERalpha-LBD). We have developed receptors that are chemically labeled with a single fluorophore in a site-specific manner. These fluorophore-labeled ERs are functional and can be used to measure directly the affinity and stability of ERalpha-LBD dimers. Our results indicate that unliganded ERalpha-LBDs exist as very stable dimers and that the dissociation rate of these dimers is slow (t(1/2)=39 +/- 3 min at 28 C) and is further slowed (< or =7-fold) by the addition of various ligands. Estrogen antagonists provide greater kinetic stabilization of the ER dimers than agonists. In addition, coactivator peptides containing the LXXLL motif selectively stabilize agonist-bound ERalpha-LBD dimers. These fluorescence-based assays for measuring the kinetic and thermodynamic stability of ER dimers provide a functional in vitro method for assessing the agonist or antagonist character of novel ligands.

1 September 2009 in RadioGraphics
Verified
Journal Article
Closed access
MGMatthew G. Gipson
Matthew G. Gipson
KCKristopher W. Cummings
Kristopher W. Cummings
KHKyle M. Hurth
Kyle M. Hurth

18 April 2020 in Neuroradiology
Verified
Journal Article
Closed access
PDF file
VPVishal Patel
Vishal Patel
CLChia-Shang J. Liu
Chia-Shang J. Liu
MSMark S. Shiroishi
Mark S. Shiroishi
KHKyle Hurth
Kyle Hurth
JCJohn D. Carmichael
John D. Carmichael
ATArthur W. Toga
Arthur W. Toga

31 August 2013 in Journal of Neural Transmission
Verified
Journal Article
Closed access
PDF file
RARichard Armstrong
Richard Armstrong
PKPaul T. Kotzbauer
Paul T. Kotzbauer
JPJoel S. Perlmutter
Joel S. Perlmutter
MCMeghan C. Campbell
Meghan C. Campbell
KHKyle M. Hurth
Kyle M. Hurth
NCNigel J. Cairns
Nigel J. Cairns

1 March 2018 in Journal of Neurosurgery
Verified
Journal Article
Closed access
WWWeijun Wang
Weijun Wang
HCHee-Yeon Cho
Hee-Yeon Cho
RRRachel Rosenstein-Sisson
Rachel Rosenstein-Sisson
NRNagore I. Marín Ramos
Nagore I. Marín Ramos
RPRyan Price
Ryan Price
Thomas ChenThomas Chen
Thomas Chen
OBJECTIVE: Glioblastoma (GBM) is the most prevalent and the most aggressive of primary brain tumors. There is currently no effective treatment for this tumor. The proteasome inhibitor bortezomib is effective for a variety of tumors, but not for GBM. The authors' goal was to demonstrate that bortezomib can be effective in the orthotopic GBM murine model if the appropriate method of drug delivery is used. In this study the Alzet mini-osmotic pump was used to bring the drug directly to the tumor in the brain, circumventing the blood-brain barrier; thus making bortezomib an effective treatment for GBM.METHODS: The 2 human glioma cell lines, U87 and U251, were labeled with luciferase and used in the subcutaneous and intracranial in vivo tumor models. Glioma cells were implanted subcutaneously into the right flank, or intracranially into the frontal cortex of athymic nude mice. Mice bearing intracranial glioma tumors were implanted with an Alzet mini-osmotic pump containing different doses of bortezomib. The Alzet pumps were introduced directly into the tumor bed in the brain. Survival was documented for mice with intracranial tumors.RESULTS: Glioma cells were sensitive to bortezomib at nanomolar quantities in vitro. In the subcutaneous in vivo xenograft tumor model, bortezomib given intravenously was effective in reducing tumor progression. However, in the intracranial glioma model, bortezomib given systemically did not affect survival. By sharp contrast, animals treated with bortezomib intracranially at the tumor site exhibited significantly increased survival.CONCLUSIONS: Bypassing the blood-brain barrier by using the osmotic pump resulted in an increase in the efficacy of bortezomib for the treatment of intracranial tumors. Thus, the intratumoral administration of bortezomib into the cranial cavity is an effective approach for glioma therapy.

16 August 2023 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
BTBen Yi Tew
Ben Yi Tew
AKAlex J. Kalfa
Alex J. Kalfa
ZYZeyi Yang
Zeyi Yang
KHKyle M. Hurth
Kyle M. Hurth
TSThomas Simon
Thomas Simon
BSBodour Salhia
Bodour Salhia
Purpose: Limited effective treatments are currently available for central nervous system (CNS) metastasis (CM). This is largely driven by the inability of current therapeutics to penetrate the blood brain barrier (BBB) and the lack of preclinical models for testing new therapies. Here we study the efficacy of AZD1390, a BBB penetrating ataxia-telangiectasia mutated inhibitor, as a radiosensitizer for breast cancer CM treatment. Experimental Design: Three patient-derived xenograft (PDX) tumors including 2 HER2+ and 1 triple-negative breast cancer harboring DNA damage response (DDR) gene mutations, were implanted subcutaneously in the flank of mice to assess tumor growth inhibition by AZD1390 combined with radiation. Animal survival was further assessed by implanting the best responding PDX model orthotopically in the brain. Results: Pretreatment with AZD1390 followed by radiation therapy inhibited growth of PDX tumors implanted in the flank, and improved survival in orthotopic models with average survival of 222 days compared with 123 days in controls. Administration of AZD1390 posttreatment for 21 days had no further benefits. While the combination therapy resulted in sustained tumor inhibition, sporadic regrowth was observed in some mice 50 to 100 days posttreatment in all models. Gene expression comparing these tumors with complete responders demonstrated changes in upregulation of oncogenic proteins, which are potential drivers of tumor growth after treatment. Conclusions: Our results demonstrate that AZD1390 effectively sensitizes breast cancer CM to radiation therapy in DDR mutant tumors. This study demonstrates the potential of using AZD1390 as a novel therapeutic agent for patients with breast cancer CM.